Switching treatment from innovator etanercept (Enbrel) to etanercept biosimilar (Benepali) in patients with a rheumatic disease in daily clinical care.

Possible determinants of the 6-months persistence of treatment with a biosimilar in patients with a rheumatic disease will be investigated. Secondary endpoints include efficacy and safety outcomes during the 1 year follow-up period.

To investigate the impact of an open label non-mandatory switching strategy from Enbrel to Benepali on drug survival, effectiveness and safety in a controlled cohort study of RA, PsA and SpA patients in daily practice.

Data will be recorded at baseline and after 6 and 12 months (+/- 2 months) of treatment.

Patients who switch treatment from Enbrel to Benepali will be asked to participate in this study. At baseline, patient and rheumatologist characteristics will be collected. Half of the included patients will randomly be asked to fill in validated questionnaires before the administration of the first Benepali injection (CEQ, SETS, BMQ, ASES). Rheumatologists will be asked to fill in the adapted CEQ, SETS and BMQ and perform an Implicit Association Test. Data on efficacy and safety will be obtained during the outpatient clinical visits performed in usual care at baseline and after 6 and 12 months of follow-up.